Close menu

May 17th, 2022 | 13:11 CEST

BioNTech, mm2 Asia, TUI - Do not oversleep!

  • entertainment
  • Investments
Photo credits:

At least in Europe, "normality" seems to have set in in everyday life - that is, concerning Corona. However, cautionary voices are already pointing to the winter season and the associated threat of new mutations. Nevertheless, given the Ukraine war and the major security-political tensions in the world, nothing is "normal." Investors should be vigilant in following geopolitical developments and not miss out on the opportunities that continually present themselves at the corporate level.

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , mm2 Asia LTD | SG1DC0000006 , TUI AG NA O.N. | DE000TUAG000

Table of contents:

    BioNTech - Momentum noticeably waning

    Every remarkable boom comes to an end at some point. In the past fiscal year, the Corona vaccine manufacturer was able to generate sales of EUR 19.3 billion and a remarkable profit of EUR 10.3 billion. The high order backlog, which could still be built up at the end of 2021, led to a positive picture at the beginning of the new fiscal year.

    The German biotech company tripled sales from EUR 2.05 billion to EUR 6.37 billion in the first quarter. Profit developed just as dynamically, jumping to EUR 3.70 billion. When presenting the figures, the Mainz-based Company reiterated its guidance for 2022 with sales of EUR 13 to 17 billion.

    On average, analysts believe that the shares have an upside potential of just under 50%. Experts also agree that it will not be possible to repeat the record results of 2021. According to analysts, profits in 2024 will only amount to a good third of the total, or around EUR 3.6 billion. The Company is currently worth around EUR 37 billion on the stock market.

    It should not be underestimated what financial strength BioNTech has received from the boom. The Company intends to use the profit for share buybacks and dividends and to invest in further research. CEO Sahin spoke of "consistent implementation of plans in the growth areas of infectious diseases and cancer treatment" when publishing the latest quarterly data. He added, "we are convinced that thanks to our innovative strength, we are well-positioned to bring several products to market in the coming years." Thus, the Mainz-based company should no longer be classified as a one-hit wonder, bringing higher share prices into perspective.

    mm2 Asia - Things are looking up again

    The Singapore-based company is broadly diversified in the entertainment sector. Through acquisitions in recent years, the Company significantly expanded its radius, starting from its core business of content production, distribution and sponsorship. The acquisition of a majority stake in the award-winning virtual reality, visual effects and computer-generated imagery studio, Vividthree Holdings, and an event production and concert promotion company, UnUsUaL Limited, gives it a clear competitive edge over rivals in this field.

    With the establishment of mmCineplexes and the acquisition of Cathay Cineplexes Pte. Ltd., mm2 Asia has also advanced to become one of the most important cinema operators in Malaysia and Singapore. After two tough years, the Corona loosening measures are now boosting the event production and concert promotion segment.

    The Company's entry into the NFT business with its marketplace called Metaviva generates a great deal of imagination. How much additional business can be generated here remains to be seen. The growth of the existing business areas alone speaks in favor of the Company, valued at around SGD 160 million on the stock exchange. According to analysts, the shares of this innovative Company are significantly undervalued. Interested investors can still acquire the share certificates at a significant discount to book value.

    TUI - The crisis seems to be over

    In connection with the recently published half-year figures, company CEO Fritz Joussen expressed his conviction that the Company will be able to return to operating profitability in the current financial year. The latest development in booking figures prompted the TUI boss to make this optimistic assessment. He said that the booking level for the summer had reached around 85% of the pre-crisis level. TUI Germany even received a third more summer bookings in April than in the same month in 2019 before the pandemic.

    In the first half of the current financial year up to the end of March 2022, the Group significantly reduced its typical seasonal loss. As of the end of September, i.e. the end of the financial year, TUI expects well over ten million travellers. Operating profit (EBIT) adjusted for special effects is expected to be "significantly positive". Nevertheless, the majority of analysts consider the share price to be exhausted.

    The development is heading in the right direction. Several factors should not be forgotten when assessing the situation. Several capital measures have noticeably increased the number of TUI shares, and the Company is currently valued at around EUR 3 billion on the stock market. The Group has also risen to number one in the industry following the bankruptcy of the British travel group Thomas Cook.

    Every crisis also represents an opportunity. Although this may sound a bit trite, there is some truth in it. During the pandemic, BioNTech was the first Corona vaccine manufacturer to soar. TUI crashed, survived and is now even the biggest player in the industry. mm2 Asia has many arrows in its quiver and is undervalued, according to analysts.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author

    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...


    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.


    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.